Santarus to Launch Novel Type 2 Diabetes Drug CYCLOSET


San Diego based Santarus, a biopharmaceutical company, announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a FDA approved prescription drug to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

According to the company, a 24-week, placebo-controlled, monotherapy study of the impact of CYCLOSET on glycemic control in 159 overweight adults (BMI ? 26.0 kg/m2 for males and ? 28.0 kg/m2 for females) with type 2 diabetes and baseline HbA1c of 7.5% – 11% indicated that once-daily morning dosing of CYCLOSET provided significant postprandial plasma glucose reductions throughout the day without increasing plasma insulin concentrations, and significantly improved HbA1c.

Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x